Preference for Gamma-hydroxybutyrate (GHB) in Current Users

Overview

Journal J Exp Anal Behav

Specialties Psychology
Social Sciences

Date 2012 Jun 14

PMID 22693361

Authors

John M Roll

Thomas Newton

Joy Chudzynski

Jennifer M Cameron

Sterling McPherson

Timothy Fong

Matt Torrington

Affiliations

Soon will be listed here.

Abstract

Gamma-hydroxybutyrate (GHB) is a drug with significant abuse potential. The present study aimed to assess the relative value of escalating doses of GHB to current GHB users via the Multiple Choice Procedure (MCP), and to validate that the dose rated highest with the MCP would be self-administered at a greater rate than placebo. Participants were 5 current GHB users who were not currently trying to stop using GHB. To examine the value of escalating doses of GHB, the following doses of GHB were used: 0 (placebo), 12.5, 25, 37.5, and 50 mg/kg. Participants typically assigned higher doses of GHB had higher crossover points on the MCP. During choice sessions, participants made repeated choices between administering GHB, placebo or nothing. All participants selected GHB exclusively (5 out of 5 instances) except for one participant who selected GHB on 4 out of 5 instances, thus 96% (i.e., 24/25) of choices were for active GHB. Based on these data, GHB appears likely to function as a dose-dependent reinforcer for humans based on our sample.

References

Ingels M, Rangan C, Bellezzo J, Clark R . Coma and respiratory depression following the ingestion of GHB and its precursors: three cases. J Emerg Med. 2000; 19(1):47-50. DOI: 10.1016/s0736-4679(00)00188-8. View

Higgins S, Roll J, Bickel W . Alcohol pretreatment increases preference for cocaine over monetary reinforcement. Psychopharmacology (Berl). 1996; 123(1):1-8. DOI: 10.1007/BF02246274. View

Mamelak M . Narcolepsy and depression and the neurobiology of gammahydroxybutyrate. Prog Neurobiol. 2009; 89(2):193-219. DOI: 10.1016/j.pneurobio.2009.07.004. View

Goodwin A, Kaminski B, Griffiths R, Ator N, Weerts E . Intravenous self-administration of γ-hydroxybutyrate (GHB) in baboons. Drug Alcohol Depend. 2010; 114(2-3):217-24. PMC: 3050086. DOI: 10.1016/j.drugalcdep.2010.10.006. View

Koek W, Mercer S, Coop A, France C . Behavioral effects of gamma-hydroxybutyrate, its precursor gamma-butyrolactone, and GABA(B) receptor agonists: time course and differential antagonism by the GABA(B) receptor antagonist 3-aminopropyl(diethoxymethyl)phosphinic acid (CGP35348). J Pharmacol Exp Ther. 2009; 330(3):876-83. PMC: 2729800. DOI: 10.1124/jpet.109.151845. View

Johanson C, de Wit H . The use of choice procedures for assessing the reinforcing properties of drugs in humans. NIDA Res Monogr. 1989; 92:171-210. View

Ferrara S, Giorgetti R, Zancaner S, Orlando R, Tagliabracci A, Cavarzeran F . Effects of single dose of gamma-hydroxybutyric acid and lorazepam on psychomotor performance and subjective feelings in healthy volunteers. Eur J Clin Pharmacol. 1999; 54(11):821-7. DOI: 10.1007/s002280050560. View

Schmitz J, Sayre S, Hokanson P, Spiga R . Assessment of the relative reinforcement value of smoking and drinking using a multiple-choice measurement strategy. Nicotine Tob Res. 2003; 5(5):729-34. DOI: 10.1080/1462220031000158618. View

Leone M, Vigna-Taglianti F, Avanzi G, Brambilla R, Faggiano F . Gamma-hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses. Cochrane Database Syst Rev. 2010; (2):CD006266. DOI: 10.1002/14651858.CD006266.pub2. View

10.

deWit H, Pierri J, Johanson C . Assessing individual differences in ethanol preference using a cumulative dosing procedure. Psychopharmacology (Berl). 1989; 98(1):113-9. DOI: 10.1007/BF00442016. View

11.

Winter J . The stimulus properties of gamma-hydroxybutyrate. Psychopharmacology (Berl). 1981; 73(4):372-5. DOI: 10.1007/BF00426468. View

12.

Gallimberti L, Spella M, Soncini C, Gessa G . Gamma-hydroxybutyric acid in the treatment of alcohol and heroin dependence. Alcohol. 2000; 20(3):257-62. DOI: 10.1016/s0741-8329(99)00089-0. View

13.

Carter L, Richards B, Mintzer M, Griffiths R . Relative abuse liability of GHB in humans: A comparison of psychomotor, subjective, and cognitive effects of supratherapeutic doses of triazolam, pentobarbital, and GHB. Neuropsychopharmacology. 2006; 31(11):2537-51. DOI: 10.1038/sj.npp.1301146. View

14.

Kam P, Yoong F . Gamma-hydroxybutyric acid: an emerging recreational drug. Anaesthesia. 1999; 53(12):1195-8. DOI: 10.1046/j.1365-2044.1998.00603.x. View

15.

Woolverton W, Johanson C . Preference in rhesus monkeys given a choice between cocaine and d,l-cathinone. J Exp Anal Behav. 1984; 41(1):35-43. PMC: 1347954. DOI: 10.1901/jeab.1984.41-i35. View

16.

Johanson C, Mattox A, Schuster C . Conditioned reinforcing effects of capsules associated with high versus low monetary payoff. Psychopharmacology (Berl). 1995; 120(1):42-8. DOI: 10.1007/BF02246143. View

17.

Kidorf M, Stitzer M, Griffiths R . Evaluating the reinforcement value of clinic-based privileges through a multiple choice procedure. Drug Alcohol Depend. 1995; 39(3):167-72. DOI: 10.1016/0376-8716(95)01136-7. View

18.

Scrima L, Hartman P, Johnson Jr F, Thomas E, Hiller F . The effects of gamma-hydroxybutyrate on the sleep of narcolepsy patients: a double-blind study. Sleep. 1990; 13(6):479-90. DOI: 10.1093/sleep/13.6.479. View

19.

Leggio L, Kenna G, Swift R . New developments for the pharmacological treatment of alcohol withdrawal syndrome. A focus on non-benzodiazepine GABAergic medications. Prog Neuropsychopharmacol Biol Psychiatry. 2007; 32(5):1106-17. DOI: 10.1016/j.pnpbp.2007.09.021. View

20.

Wang Y, Swick T, Carter L, Thorpy M, Benowitz N . Safety overview of postmarketing and clinical experience of sodium oxybate (Xyrem): abuse, misuse, dependence, and diversion. J Clin Sleep Med. 2009; 5(4):365-71. PMC: 2725257. View